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Abstract
Background: Regression of hepatic fibrosis in patients with autoimmune hepatitis (AIH) has been
described in response to immunosuppressive therapy. These studies, however, besides being few
in number, were conducted on adult populations. Our aim was to assess the regression of hepatic
fibrosis, using morphometric assessment of fibrosis versus semi-quantitative methods, in children
with AIH who achieved clinical and biochemical remission. Thirteen patients who achieved clinical
and biochemical remission were included in the study, out of 62 children with AIH. Repeat biopsy
was performed after 6 to 12 months of clinical and biochemical remission. Morphometric
assessment of fibrosis was performed and correlated with METAVIR and Ishak semi-quantitative
scores.
Results:  The study group included eight male and five female patients. The median age at
presentation was 4 years (range 2 to 12 years). The mean duration of treatment was 22 ± 7.3
months, and the mean interval between biopsies was 26.2 ± 6.5 months. Following therapy, there
was significant reduction in aspartate aminotransferase, ALT and IgG levels as well as improvement
of necroinflammation. The mean fibrosis scores were significantly decreased from 4.5 ± 1.19 and
2.9 ± 0.7 before therapy to 2.7 ± 1.16 and 2 ± 0.8 after treatment as assessed by Ishak and
METAVIR scores, respectively (P = 0.001 and 0.004). The mean morphometric assessment of
fibrosis before treatment was 20% ± 9.7 and following therapy it decreased to 5.6% ± 3.9 (P =
0.000).
Conclusion:  Significant regression of fibrosis in paediatric AIH could occur with current
therapeutic regimens. Morphometric assessment of fibrosis is more sensitive than semi-
quantitative methods to identify changes in fibrosis.
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Background
Autoimmune hepatitis (AIH) remains an enigmatic con-
dition that affects children of all ages. It accounts for 2%
to 5% of paediatric liver disease; however, the disease
process in children appears to be more severe at presenta-
tion than commonly seen in adults, perhaps because of
delay in diagnosis. Over 50% of children have cirrhosis at
accession, and the disease commonly has an aggressive
course [1].
AIH reflects a complex interaction between triggering fac-
tors, autoantigens, genetic predisposition and immu-
noregulatory networks [2]. Currently, the basic treatment
of AIH is prednisone and/or azathioprine. Treatment aims
at obtaining full remission not only at the clinical and
biochemical levels but also at the histological level.
Remission connotes disappearance of symptoms, lack of
biochemical manifestations of inflammation (aspartate
aminotransferase (AST) level should not be more than
twice the upper normal limit, globulin levels should be
normal) with the histological findings showing lack of
activity or minimal activity of the process [3,4].
Cirrhosis is an end-stage process of chronic progressive
scarring inflammation produced by many causes. Once
cirrhosis is established, it had been considered to be irre-
versible. When complications of cirrhosis such as ascites,
severe encephalopathy and jaundice with variceal bleed-
ing develop, the survival of cirrhotic patients becomes
short and lethality is unavoidable. However, reports
about a variety of liver disease states suggest that even
established cirrhosis might be reversible with certain ther-
apeutic regimens. Regression of fibrosis has followed
phlebotomy for haemochromatosis [5], relief of chronic
biliary obstruction [6] and bone marrow transplantation
for thalassemia [7]. Reports suggest improvement of cir-
rhosis in patients with primary biliary cirrhosis treated
with ursodeoxycholic acid and methotrexate [8], and also
in patients with Wilson's disease treated with penicilla-
mine [9]. Recently, there has been a documented regres-
sion of fibrosis in several patients of chronic hepatitis B
and C treated with antiviral agents [10-13]. These observa-
tions in humans have been supported by murine models
of hepatic injury in which biliary fibrosis has decreased
after biliary decompression [14] and rabbit models in
which liver fibrosis has regressed after treatment of schis-
tosomiasis [15].
Few reports are available on the regression of hepatic
fibrosis in patients with autoimmune hepatitis in
response to immunosuppressive therapy [16,17]. All
these studies, however, were conducted on adult popula-
tions and only one, so far, was conducted on paediatric
patients [18]. Morphometric assessment of fibrosis by
image analysis is becoming more sensitive and accurate
than semi-quantitative methods for the assessment of
hepatic fibrosis [19,20].
The aim of this study was to assess the possible regression
of hepatic fibrosis, using the morphometric assessment of
fibrosis versus semi-quantitative methods, in children
with AIH treated with prednisone and/or azathioprine
who achieved clinical and biochemical remission.
Methods
Study population
Thirteen patients (eight males and five females) with AIH,
who achieved clinical and biochemical remission in
response to treatment with prednisone and/or azathio-
prine, were included out of 62 patients with AIH who
were seen at Mansoura University Children's Hospital,
Paediatric GI and Hepatology Unit between 1999 and
2007. The remaining 49 patients were not included
because they either did not have significant fibrosis (≤ 2/
6, Ishak score) (0 or F1, METAVIR) at presentation, not
enough time had elapsed for post-remission biopsy, had
relapses, or failed to give consent.
Autoimmune hepatitis was diagnosed if the patient had
chronically elevated serum aminotransferase levels,
hypergammaglobulinaemia, positive autoantibodies
(antinuclear antibody (ANA), anti-smooth muscle anti-
body (SMA), anti liver-kidney microsomal (LKM) anti-
body type 1), histopathological features compatible with
autoimmune hepatitis on liver biopsy, and no evidence of
viral infection (hepatitis B and C), metabolic (Wilson's
disease, α1-antitrypsin deficiency, hemochromatosis) or
drug-induced liver disease. We applied the revised scoring
system for diagnosis of autoimmune hepatitis with inter-
pretation of aggregated score; Definite AIH >15 and prob-
able AIH 10 to 15 [21]. Included children were divided
into two groups: Type 1 (ANA/SMA positive) and Type 2
(LKM-1 positive).
Treatment regimen and outcome
After diagnosis, treatment was initiated by prednisone; 2
mg/kg/day (up to 60 mg) for 2 weeks, then gradually
tapered over 6 to 8 weeks, guided by the clinical and bio-
chemical responses to a maintenance dose of 0.1 to 0.2
mg/kg/day or 5 mg daily, plus azathioprine 1 to 2 mg/kg/
day (unless it is contraindicated due to cytopenia). Remis-
sion was defined as disappearance of symptoms with no
flares, improvement of aminotransferase to less than
twice normal (maintained for at least 1 to 2 years), resto-
ration of serum bilirubin and γ globulin level to normal,
and histological findings showing lack of activity or min-
imal activity. The included children underwent a second
biopsy after 1 to 2 years of remission.Fibrogenesis & Tissue Repair 2009, 2:2 http://www.fibrogenesis.com/content/2/1/2
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Histological assessment
After obtaining an informed and written consent, 26 liver
biopsies from these 13 children were obtained (pre and
post-treatment) by blind percutaneous biopsy (Bard gun
biopsy with Tru-cut needle, gauge 16). The length of liver
biopsies was 1.5 cm or more; the number of portal tracts
was six or more. The cores were fixed in 10% formalde-
hyde-saline and processed according to routine histologi-
cal techniques, until paraffin embedding.
For routine pathological diagnosis, sections were stained
with haematoxylin and eosin, Masson's trichrome, and
periodic acid shift before and after diastase digestion. His-
tological features were semi-quantitatively graded accord-
ing to the Ishak modified Knodell Score [22] and
METAVIR system [23]. The histological evaluation was
performed systemically by one hepatopathologist (KZ)
who was blinded to the clinical and serological data.
The morphometric assessment of liver fibrosis was per-
formed by the fully automated Leica image processor with
automated stage and Leica Quin software 2004. The liver
biopsy slide, stained with Sirus red, was placed on the x-y
motorized stage of Leica microscope. At a magnification
of ×10, automated sequential digitalized images were
taken and stored, then a mosaic picture was created
including all the images with minimal field overlapping.
This enables fibrosis assessment of the entire core at the
same time. After interactive threshold, the image was con-
verted into a binary image. Artefacts created during slide
preparation were eliminated by both automatic and inter-
active procedures (Figure 1a to 1d). The area of the liver
parenchyma was considered the reference area, then the
fractional surface occupied by fibrosis was measured
within the above-defined area.
Statistical analysis
The statistical analysis of data was done using SPSS pro-
gram statistical package for social science version 10. The
description of the data was performed in the form of
mean (±) standard deviation for quantitative data and fre-
quency and proportion for qualitative data. Non-para-
metric data were tested by Kolmogrov-Smirnov test and
was represented as median (minimum-maximum). Pear-
son correlation was applied to test the association
between morphometry, Ishak and METAVIR.
The analysis of the data was done to test statistically signif-
icant differences between groups. Paired sample t-test was
used to compare one group at different times, and Wil-
Morphometric assessment of liver fibrosis in post-treatment biopsy using mosaic picture Figure 1
Morphometric assessment of liver fibrosis in post-treatment biopsy using mosaic picture. a) Post-treatment 
mosaic picture of 93 microscopic fields (Sirus redx100). b) Delineation of the whole liver core (mosaic picture). c) Computer-
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coxon test was used to compare non-parametric data at
different times. P is significant if ≤ or = 0.05 at confidence
interval 95%.
Results
Demographic and biochemical results
The median age at presentation was 4 years (range 2 to 12
years). Ten children were classified as Type 1 while the
remaining three were Type 2. At presentation, patients
had elevated alanine aminotransferase (ALT) levels
(median = 243 IU/l, range 19 to 870 IU/l), AST levels
(median = 170 IU/l, range 19 to 800 IU/l), and immu-
noglobulin G (IgG) levels (median = 27 mg/dl, range 13
to 48 mg/dl) (Table 1). The median albumin level was 3.7
g/dl (range 2.9 to 5.2 g/dl), and the median platelet count
was 189,000 cells/mm3 (range 78,000 cells/mm3  to
400,000 cells/mm3). Bilirubin level was 4.5 mg/dl (range
0.5 to 17.0 mg/dl). Their prothrombin times ranged from
11 to 17 seconds. All the included patients were classified
according to the revised IAHG scoring system before treat-
ment as definite AIH, with score range from 16 to 20.
There was no post-treatment reassessment, as all the
included children were definite AIH before treatment
(score>15).
Duration of therapy and follow up
The follow up period varied from 2 years to 7.5 years
(mean = 4.07 ± 2.9 years). The mean duration of treat-
ment was 22 ± 7.3 months. The mean interval between
diagnostic biopsies and those made to determine discon-
tinuation of treatment was 26.2 ± 6.5 months. The mean
time elapsed from clinical and biochemical remission till
liver biopsy 17.8 ± 8.5 months. Following therapy, there
was a significant reduction in AST, ALT and IgG levels as
shown in Table 1.
Histological assessment
The mean necroinflammation score before treatment was
8.07 ± 3.5 and 2.2 ± 0.9 as assessed by Ishak and METAVIR
scores respectively. Following treatment, there was a sig-
nificant reduction in necroinflammation (4.6 ± 2.4 and
1.07 ± 0.6 as assessed by Ishak and METAVIR scores
respectively), P = 0.004 and 0.001 (Table 2).
The stage of fibrosis was assessed semi-quantitatively by
both Ishak and METAVIR scores. The mean fibrosis score
before treatment was 4.5 ± 1.19 and 2.9 ± 0.7 respectively.
Following treatment, it decreased to 2.7 ± 1.16 and 2 ±
0.8. Such reduction was statistically significant (P = 0.001
and 0.004 for Ishak and METAVIR scores, respectively). In
three children the METAVIR score remained unchanged
(Table 3).
The mean morphometric assessment of fibrosis before
treatment was 20% ± 9.7% and following therapy it
decreased to 5.6% ± 3.9% (P = 0.000). In the three chil-
dren whose METAVIR score remained unchanged, how-
ever, morphometry revealed a significant reduction in the
degree of fibrosis (P < 0.001). On pre-treatment liver
biopsies, Pearson correlation test revealed good correla-
tion between Ishak and morphometry (correlation coeffi-
cient: 0.757, P < 0.01), and between METAVIR and
morphometry (correlation coefficient: 0.635, P < 0.05).
Furthermore, on post-treatment liver biopsies, there was a
Table 1: Laboratory investigations of the studied group before and after treatment
Before treatment After treatment
Serial ALT AST IgG ALT AST IgG
1 673 600 21.8 10 45 12
2 540 560 13.3 17 47 14.5
3 5 8 5 4 1 2 4 83 03 61 8
4 8 38 51 7 . 3 3 0 2 2 1 4 . 4
5 5 0 9 5 2 84 04 51 2 . 6
6 8 7 0 8 0 0 2 35 25 31 6 . 3
7 1 5 6 1 7 0 3 23 44 91 4 . 8
8 314 100 27 102 91 18
9 3 9 1 9 2 82 61 51 4 . 4
10 35 40 17.7 18 22 17
11 19 26 20.6 20 24 15
12 243 230 27.8 40 48 14.4
13 502 671 30.5 19 33 16
Mean 316.0769 292.9231 25.7692 33.6923 40.7692 15.1846
Median 243 170 27 30 45 14.8
Std. Deviation 287.4275 278.2117 8.7248 23.5527 19.5796 1.8343
Minimum 19 19 13.3 10 15 12
Maximum 870 800 48 102 91 18Fibrogenesis & Tissue Repair 2009, 2:2 http://www.fibrogenesis.com/content/2/1/2
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good correlation between Ishak and morphometry (corre-
lation coefficient: 0.643, P < 0.05), and between METAVIR
and morphometry (correlation coefficient: 0.636, P <
0.05) as well.
Discussion
Hepatic fibrosis is the common end point for most types
of chronic liver injury. It is usually considered to be an
irreversible process, especially when there is evidence of
cirrhosis [24]. Recent data have challenged this belief by
showing that hepatic fibrosis is a dynamic process involv-
ing an imbalance between the deposition and the degra-
dation of fibrillar collagens and other extracellular matrix
proteins [25]. Hepatic fibrosis is amenable to intervention
by removing the insult and stopping the persistent inflam-
matory stimuli [26].
We studied thirteen patients with documented cirrhosis or
extensive fibrosis at the time of diagnosis of AIH in whom
clinical and biochemical remission was achieved by pred-
nisone and/or azathioprine therapy, with significant
reduction in the necroinflammatory injury in post-treat-
ment liver biopsies. We discovered a significant regression
of fibrosis in these patients after 6 to 12 months of clinical
and biochemical remission.
Previous studies have demonstrated that hepatic inflam-
mation stimulates perivascular hepatic stellate cells by
cytokines, such as transforming growth factor β1 (TGF-b),
These activated stellate cells are transformed into myofi-
broblasts; they proliferate, migrate, and degrade the nor-
mal extracellular matrix and replace it with fibril-forming
collagens types I and III [27]. The matrix proteins accumu-
late because tissue inhibitors retard the counteractive deg-
radative actions of matrix metalloproteinases [28].
Suppression of inflammatory activity promotes disap-
pearance of the metalloproteinase inhibitors, degradation
of the fibrotic liver matrix by unrestricted metalloprotein-
ases, and apoptosis of the hepatic stellate cells [29,30].
Our findings suggest that treatment with prednisone and/
or azathioprine may inhibit the inciting stimulus for
Table 2: Activity scores of the studied group before and after 
treatment
Activity before treatment Activity after treatment
Serial Ishak METAVIR Ishak METAVIR
14 1 4 1
29 3 1 0
31 1 3 6 1
45 1 6 1
58 2 5 1
68 2 8 2
71 3 3 6 2
89 3 8 2
91 0 3 6 1
10 3 1 3 1
11 2 1 0 0
12 13 3 4 1
13 10 3 3 1
Mean 8.0769 2.2308 4.6154 1.0769
Median 9.0000 3.0000 5.0000 1.0000
Std. Deviation 3.5931 .9268 2.4337 .6405
Minimum 2.00 1.00 .00 .00
Maximum 13.00 3.00 8.00 2.00
Table 3: Fibrosis scores of the studied group before and after treatment (Ishak, METAVIR, and Morphometry)
SERIAL Before Fibrosis After Fibrosis
Ishak METAVIR Morphometry% Ishak METAVIR Morphometry%
13 2 9 3 2 3
2 5 31 8 1 12
3 5 33 6 . 3 3 28 . 1
4 5 32 7 4 31 1
5 4 31 5 1 12
6 3 21 3 4 31 0
7 5 32 5 4 31 . 1
8 6 43 0 4 31 2
9 5 33 2 3 21 0
10 3 2 7.9 2 1 3.4
11 3 2 5.3 1 1 1.8
12 6 4 20 3 2 5
13 6 4 21.8 3 2 3.6
Mean 4.5385 2.9231 20.0231 2.7692 2 5.6154
Median 5 3 20 3 2 3.6
Standard deviation 1.1983 0.7596 9.7827 1.1658 0.8165 3.9964
Minimum 3 2 5.3 1 1 1.1
Maximum 6 4 36.3 4 3 12Fibrogenesis & Tissue Repair 2009, 2:2 http://www.fibrogenesis.com/content/2/1/2
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fibrogenesis and facilitate these anti-fibrotic actions in
AIH by suppressing liver inflammation.
On the other hand, a glucocorticoid response element has
been described in the human TGF-b1 gene promoter
which may inhibit its expression [31]. Thus, corticoster-
oids may impair activation of TGF-b [32], alter its binding
characteristics to matrix sites [33] and affect the ligation of
TGF-b activator protein to the TGF-b element [34]. These
putative anti-fibrotic actions of corticosteroids may com-
plement their known anti-inflammatory effects to retard
fibrogenesis and favour the counter-regulatory mecha-
nisms of fibrinolysis [35,36].
Regression of hepatic fibrosis in AIH has been reported in
adult patients [16,17,37-39], and there is one report on
regression of hepatic fibrosis in paediatric cases of AIH
[18]. In all these studies the assessment of fibrosis was
done only semi-quantitatively by applying Ishak score. In
our study we assessed hepatic fibrosis by semi-quantita-
tive methods applying both Ishak and METAVIR scores
and by a quantitative assay, morphometry. Regression of
fibrosis was evident by both methods; however, by mor-
phometry reduction of fibrosis was more significant.
Moreover, cases in which no significant reduction of
fibrosis was assessed by the semi-quantitative methods,
morphometry could show a significant change. Ferreira et
al found no change in fibrosis score in 25% of their
patients but in one patient incomplete cirrhosis devel-
oped into complete cirrhosis [18]. In 70% of their patients
there was reduction in fibrosis; however, the meantime
elapsed from remission to liver biopsy was longer (4.1 ±
1.5 years) than in our study (17.8 ± 8.5 months) [18]. To
the best of our knowledge, this is the first time that fibro-
sis reversibility has been assessed by the morphometric
method in paediatric patients. Our findings suggest that
quantitative assessment of fibrosis may be more sensitive
in assessing regression of fibrosis following treatment of
AIH. It has the benefit of avoiding the inter-observer vari-
ation in the assessment of fibrosis by semi-quantitative
methods. Also, morphometry can assess the actual
amount of fibrosis and not only its pattern, as in semi-
quantitative methods. Moreover, application of mor-
phometry on a mosaic picture of the entire core enabled
the assessment of the portal as well the parenchymal
fibrosis at the same time.
Conclusion
Hepatic fibrosis and early cirrhosis are amenable to regres-
sion in patients with AIH achieving clinical and biochem-
ical remissions in response to treatment. Early inclusion
of prednisone and/or azathioprine might have great ben-
efits on regression of fibrosis.
Morphometry is a more sensitive method to assess hepatic
fibrosis regression in comparison with semi-quantitative
methods (Ishak and METAVIR). Application of mosaic
technology enables image analysis of the entire core with-
out selection bias of certain areas.
Abbreviations
AIH: Autoimmune Hepatitis; ALT: Alanine Aminotrans-
ferase; ANA: Anti-nuclear Antibody; AST: Aspartate Ami-
notransferase; IgG: Immunoglobulin G; LKM: anti-liver-
kidney Microsomal: SAM: Anti-smooth Muscle Antibody;
TGF-b: Transforming Growth Factor Beta.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AA conceived of the study and participated in its design
and coordination and helped to draft the manuscript. KZ
carried out the histological and morphometric studies,
participated in study design and helped to draft the man-
uscript. AI participated in the acquisition and interpreta-
tion of data and participated in drafting the manuscript.
GS and MA were involved in revising the manuscript crit-
ically for important intellectual content. AAA participated
in the design of the study and performed the statistical
analysis. All authors read and approved the final manu-
script.
References
1. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG,
McCartney M, Mowat AP, Vergani D, Mieli-Vergani G: Autoim-
mune hepatitis in childhood. A 20 year survey.  Hepatology
1997, 25:541-547.
2. Czaja AJ, Freese DK: Diagnosis and treatment of autoimmune
hepatitis.  Hepatology 2002, 36:479-497.
3. Czaja AJ, Menon KVN, Carpenter HA: Sustained remission after
corticosteroid therapy of type 1 autoimmune hepatitis: a
retrospective analysis.  Hepatology 2002, 35:890-897.
4. Baranov AA, Kaganov BS, Gundobina OS, Zainudinov ZM: Autoim-
mune hepatitis in children.  Int Pediatr 2003, 18:23-29.
5. Powell LW, Kerr JF: Reversal of cirrhosis in idiopathic haemo-
chromatosis following long-term intensive venesection ther-
apy.  Australas Ann Med 1970, 19:54-57.
6. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF,
Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Lévy P:
Regression of liver fibrosis after biliary drainage in patients
with chronic pancreatitis and stenosis of the common bile
duct.  N Engl J Med 2001, 344:418-423.
7. Muretto P, Angelucci E, Lucarelli G: Reversibility of cirrhosis in
patients cured of thalessemia by bone marrow transplanta-
tion.  Ann Intern Med 2002, 136:667-672.
8. Kaplan MM, DeLellis RA, Wolfe HJ: Sustained biochemical and
histologic remission of primary biliary cirrhosis in response
to medical treatment.  Ann Intern Med 1997, 126:682-688.
9. Falkmer S, Samuelson G, Sjolin S: Penicillamine-induced normal-
ization of clinical signs, and liver morphology and histochem-
istry in a case of Wilson's disease.  Pediatrics 1970, 45:260-268.
10. Dufour JF, DeLellis R, Kaplan MM: Regression of hepatic fibrosis
in hepatitis C with long-term interferon treatment.  Dig Dis Sci
1998, 43:2573-2576.
11. Poynard T, McHutchinson J, Manns M, Trepo C, Lindsay K, Goodman
Z, Ling MH, Albrecht J: Impact of interferon alpha-2b and riba-
virin on liver fibrosis in patients with chronic hepatitis C.  Gas-
troenterology 2002, 122:1303-1313.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Fibrogenesis & Tissue Repair 2009, 2:2 http://www.fibrogenesis.com/content/2/1/2
Page 6 of 6
(page number not for citation purposes)
12. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH: Resolu-
tion of chronic delta hepatitis after 12 years of interferon alfa
therapy.  Gastroenterology 1999, 117:1229-1233.
13. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Bur-
chardt E, Schoonhoven R, Brenner DA, Fried MW: Decreasing
fibrogenesis: an immunohistochemical study of paired liver
biopsies following lamivudine therapy for chronic hepatitis
B.  J Hepatol 2001, 35:749-755.
14. Zimmerman H, Reichen J, Zimmerman A, Sagesser H, Thenisch B,
Hoflin F: Reversibility of secondary biliary fibrosis by biliodi-
gestive anastomosis in the rat.  Gastroenterology 1992,
103:579-589.
15. Dunn MA, Cheever AW, Paglia LM, Kelly EP, Duvall RH, Andrade ZA,
Goldner FH: Reversal of advanced liver fibrosis in rabbits with
Schistosomiasis japonica.  Am J Trop Med Hyg 1994, 50:499-505.
16. Dufour IF, Dellelis R, Kaplan MM: Reversibility of hepatic fibrosis
in autoimmune hepatitis.  Ann Intern Med 1997, 127:981-985.
17. Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoim-
mune hepatitis with corticosteroid therapy.  J Clin Gastroenterol
2001, 32:428-430.
18. Ferreira AR, Roquete MLV, Toppa NH, Fonseca de Castro LPF,
Fagundes EDT, Penna FJ: Effect of treatment on hepatic histopa-
thology in children and adolescents with autoimmunehepa-
titis.  J Pediatr Gastroenterol Nutr 2008, 46:65-70.
19. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H,
Maïga MY, Gallois Y, Calès P: Histopathological evaluation of
liver fibrosis: quantitative image analysis Vs semi-quantita-
tive scores.  J Hepatol 1998, 28:439-446.
20. Goodman ZD, Becker RL, Pockros PJ, Afdhal NH: Progression of
fibrosis in advanced chronic hepatitis C: evaluation by mor-
phometric image analysis.  Hepatology 2007, 45:886-894.
21. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL,
Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT,
Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH,
Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC,
Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M:
International Autoimmune Hepatitis Group Report: review
of criteria for diagnosis of autoimmune hepatitis.  J Hepatol
1999, 31:929-938.
22. Ishak K, Baptista A, Bianchi L, Callea F, Groote JD, Gudat F, Denk H,
Desmet V, Korb G, MacSween RN: Histological grading and stag-
ing of chronic hepatitis.  J Hepatol 1995, 22:696-699.
23. Bedossa P, Poynard T: An algorithm for the grading of activity
in chronic hepatitis C.  Hepatology 1996, 24:289-293.
24. Friedman SL: The cellular basis of hepatic fibrosis: mechanisms
and treatment strategies.  N Engl J Med 1993, 328:1828-1835.
25. Olaso E, Friedman SL: Molecular regulation of fibrogenesis.  J
Hepatol 1998, 29:836-847.
26. Bonis PA, Friedman SL, Kaplan MM: Is liver fibrosis reversible?  N
Engl J Med 2001, 344:52-454.
27. Friedman SL: Seminars in medicine of the Beth Israel Hospital,
Boston. The cellular basis of hepatic fibrosis. Mechanisms
and treatment strategies.  N Engl J Med 1993, 328:1828-1836.
28. Friedman SL: Molecular regulation of hepatic fibrosis, an inte-
grated cellular response to tissue injury.  J Biol Chem 2000,
275:2247-2250.
29. Murphy FR, Issa R, Zhou X, Rhatnarajah S, Nagase H, Arthur MJ,
Benyon C, Iredale JP: Inhibition of apoptosis of activated
hepatic stellate cells by tissue inhibitor of metalloproteinase-
1 is mediated via effects on matrix metalloproteinase inhibi-
tion: implications for reversibility of liver fibrosis.  J Biol Chem
2002, 277:11069-11076.
30. Issa R, Williams E, Trim N, Kendall T, Arthur MJP, Reichen J, Benyon
RC, Iredale JP: Apoptosis of hepatic stellate cells: involvement
in resolution of biliary fibrosis and regulation by soluble
growth factors.  Gut 2001, 48:548-557.
31. Parrelli JM, Meisler N, Cutroneo KR: Identification of a glucocor-
ticoid response element in the human transforming growth
factor beta 1 gene promoter.  Int J Biochem Cell Biol 1998,
30:623-627.
32. Cai J, Zheng T, Lotz M, Zhang Y, Masood R, Gill P: Glucocorticoids
induce Kaposi's sarcoma cell proliferation through the regu-
lation of transforming growth factor beta.  Blood 1997,
89:1491-1500.
33. Centrella M, McCarthy TL, Canalis E: Glucocorticoid regulation
of transforming growth factor beta 1 activity and binding in
osteoblast enriched cultures from fetal rat bone.  Mol Cell Biol
1991, 11:4490-4496.
34. Shukla A, Meisler N, Cutroneo KR: Perspective article: trans-
forming growth factor-beta: cross road of glucocorticoid and
bleomycin regulation of collagen synthesis in lung fibrob-
lasts.  Wound Repair Regen 1999, 7:133-140.
35. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ: Regulation of
cytokine and cytokine receptor expression by glucocorti-
coids.  J Leukoc Biol 1996, 60:563-572.
36. Almawi WY: Molecular mechanisms of glucocorticoid effects.
Mod Asp Immunobiol 2001, 2:78-82.
37. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali
S, Rakhshani N, Tavangar SM, Sedaghat M, Alimohamadi SM: Impact
of immunosuppressive treatment on liver fibrosis in autoim-
mune hepatitis.  Dig Dis Sci 2005, 50:547-551.
38. Czaja AJ, Carpenter HA: Decreased fibrosis during corticoster-
oid therapy of autoimmune hepatitis.  J Hepatol 2004,
40:646-652.
39. Schvarez R, Glaumann H, Weiland O: Survival and histological
resolution of fibrosis in autoimmune chronic active hepatitis.
J Hepatol 1993, 18:15-23.